IN8bio reports Q2 2026 results, GBM survival data and TCE platform progress

IN8bio reported financial results and pipeline updates for the second quarter ended June 30, 2026, in a release dated August 6, 2026.

On the glioblastoma program, the company presented updated clinical data at the 2026 American Society of Clinical Oncology Annual Meeting showing median progression-free survival of 13.0 months versus 6.6 months for contemporaneously enrolled patients receiving only standard-of-care, and median overall survival exceeding 19.5+ months versus 13.2 months for standard-of-care¹. The company also noted that approximately 43% of repeat-dose patients remained alive at 24 months compared with 20% of standard-of-care patients¹. Separately, IN8bio said it published the first peer-reviewed clinical results of DeltEx DRI in newly diagnosed glioblastoma in The Journal of Clinical Oncology, reporting that among all patients treated, no dose-limiting toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity syndrome were observed¹.

On its engager platform, the company said it is advancing INB-619, a CD19-targeting γδ T cell engager for oncology and autoimmune diseases, into IND-enabling studies following encouraging early preclinical data demonstrating complete B cell depletion, robust γδ T cell expansion, and minimal CRS-associated cytokine release, including IL-6 and TNF-α¹, and remains on track to report initial in vivo preclinical data in the second half of 2026¹.

Among upcoming milestones, the company said it plans to report on FDA discussions regarding the potential regulatory pathways for the DeltEx DRI GBM program¹ and provide an INB-100 program clinical update at a scientific meeting in late 2026¹.

Financially, IN8bio reported cash of $18.0 million as of June 30, 2026, compared with $13.2 million for the comparable prior year period¹, and a net loss of $4.8 million, or $0.25 per basic and diluted common share, for the three months ended June 30, 2026, compared with a net loss of $5.1 million, or $1.24 per share, in the comparable prior year period¹.